Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study

Blood

Volumn 114, Issue 8, 2009, Pages 1489-1497

  Reece, Donna E ^a   Sanchorawala, Vaishali ^b   Hegenbart, Ute ^c   Merlini, Giampaolo ^d   Palladini, Giovanni ^d   Fermand, Jean Paul ^e   Vescio, Robert A ^f   Liu, Xiangyang ^g   Elsayed, Yusri A ^g   Cakana, Andrew ^g   Comenzo, Raymond L ^h  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF PAVIA   (Italy)

^e SAINT LOUIS HOSPITAL   (France)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g JOHNSON AND JOHNSON   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; AMYLOIDOSIS; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HERPES; HUMAN; HUMAN TISSUE; HYPERHIDROSIS; HYPESTHESIA; HYPOTENSION; INFLUENZA; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUROLOGIC DISEASE; NIGHT SWEAT; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RELAPSE; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; SORE THROAT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME;

EID: 70349575412     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203398     Document Type: Article

References (39)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898-909.
2. Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin lightchain (Al) amyloidosis. Contrib Nephrol. 2007; 153:195-210.
3. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-2530.
4. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-1822.
5. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007;5(2): 179-187.
6. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica. 2007;92(10):1302-1307. (Pubitemid 350144146)
7. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
8. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93(3):1062-1066. (Pubitemid 29067872)
9. Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004;104(12):3520-3526.
10. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10):1415- 1418. (Pubitemid 350144161)
11. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202-1207.
12. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938.
13. Guidelines Working Group of UK Myeloma Forum; British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125(6):681-700.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™ Multiple Myeloma (V. 2.2009). http://www.nccn.org/ professionals/physician-gls/PDF/myeloma.pdf. Accessed February 2, 2009.
15. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276-4282. (Pubitemid 34627192)
16. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007; 357(11):1083-1093. (Pubitemid 47443213)
17. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant. 2000;25(5):465-470. (Pubitemid 30137858)
18. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28(7):637-642. (Pubitemid 33014596)
19. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105(7):2949-2951. (Pubitemid 40446290)
20. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076. (Pubitemid 32691956)
21. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12(6):664-689.
22. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-3560.
23. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
24. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Significant activity of bortezomib-based therapy in patients with primary systemic (AL) amyloidosis [abstract]. Blood. 2008;112(11 suppl):Abstract 869.
25. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298.
26. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis and light chain deposition disease (LCDD) with the combination of bortezomib and dexamethasone [abstract]. Blood. 2007;110(11 suppl):64a.
27. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-3120. (Pubitemid 46638949)
28. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-328. (Pubitemid 41098849)
29. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165-172. (Pubitemid 39371809)
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617.
31. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-2498. (Pubitemid 41007864)
32. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
33. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol. 2005;18(4):673-688.
34. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78-84. (Pubitemid 36819341)
35. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2): 457-464.
36. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496. (Pubitemid 46105943)
37. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470. (Pubitemid 46105939)
38. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377-2380. (Pubitemid 36302084)
39. Hoffman JE, Hassoun H, Landau H, et al. Early adjuvant treatment after risk-adapted autologous stem cell transplant for systemic light-chain amyloidosis: increased hospitalizations and impaired immune recovery but improved responses and overall survival [abstract]. Blood. 2008;112(11 suppl):Abstract 3329.